Asia
The past two decades were all about nucleic acid reading and writing. The next is about delivering DNA and RNA, Yogev Debbi, CEO of Mana.bio, told BioSpace in an interview.
Artificial intelligence and machine learning could change the face of cancer diagnostics. BioSpace spoke with the University of Waterloo, Gina Life and OncoHost to find out how.
AI/ML applications are being deployed at large pharmaceutical companies, but in order to truly maximize their potential, better infrastructure is needed. AION Labs believes it is answering that call.
A pre-specified interim analysis of Junshi Biosciences’ Phase III Neotorch trial showed its anti-PD-1 monoclonal antibody, toripalimab, met its primary endpoint in non-small cell lung cancer (NSCLC).
Twist Bioscience announced a partnership with Astellas Pharma on Monday, seeking to discover antibodies against several targets to hit on curative therapies for hard-to-treat diseases.
Merck entered into a license and collaboration agreement with Chinese company Kelun-Biotech to develop seven antibody-drug conjugates candidates against oncology targets.
The FDA granted priority review to Takeda’s Biologics License Application for TAK-003, a dengue vaccine candidate. The vaccine to date is only approved for use in Indonesia.
With military precision and academic ingenuity, Israel is building a thriving biotech ecosystem. Venture capitalists would do well to pay attention.
Novartis, GlaxoSmithKline and Sanofi have announced plans for significant cutbacks and changes in their labor force overseas for financial, operational and logistical reasons.
Zealand Pharma and Novo Nordisk linked resources to commercialize Zegalogue for severe hypoglycemia. For that and more from a busy week across the globe, see inside.
PRESS RELEASES